Drug intelligence / Profile preview

SDV2104

Development stage: Unknown
Lead developer: SYNDIVIA
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

SDV2104 is an antibody-drug conjugate (ADC) currently in the discovery stage of development by SYNDIVIA. The drug is engineered using SYNDIVIA's proprietary GeminiMab platform, which is designed to provide highly stable and homogeneous ADCs with an improved therapeutic index. While the specific molecular target, cytotoxic payload, and intended clinical indications remain undisclosed, the program represents part of the company's internal pipeline of next-generation site-specific conjugates.

Beyond the preview

Go deeper on SDV2104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SDV2104.

Explore the full profile